Last reviewed · How we verify

NCT07340281

Biomarkers for Exercise

Recruiting now NA Last updated 31 March 2026
What this trial tests

NA trial testing Exercise Intervention in Anxiety Disorders in 30 participants. Currently enrolling.

Timeline
6 March 2026
Primary endpoint
1 August 2027
15 January 2028

Quick facts

Lead sponsorNYU Langone Health
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingsingle
Primary purposebasic science
Enrollment30
Start date6 March 2026
Primary completion1 August 2027
Estimated completion15 January 2028
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

NYU Langone Health — full company profile →

Who can join

Adults 18 to 50, any sex, with Anxiety Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overarching objective is to examine the brain-based biological mechanistic pathway by which exercise exerts anxiolytic effects. The investigators will measure brain-derived markers of mitochondrial metabolism (acetyl-L-carnitine \[LAC\]) and inflammation (interleukin-6 \[IL-6\]) using innovative technology to isolate neuronal exosomes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Exercise Intervention

Trials testing the same drug.

Other recruiting trials for Anxiety Disorders

Currently open trials in the same condition.

Other NYU Langone Health trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07340281.